Biopharmaceutical company Invivyd Inc (Nasdaq:IVVD) on Friday reported data showing continued in vitro activity of its mAb candidate, VYD222 (pemivibart), against prevalent SARS-CoV-2 variants, including KP.1.1 FLiRT and KP.3.
These variants are projected to become dominant strains.
The data aligns with independent research suggesting VYD222's effectiveness against these variants.
Invivyd's next mAb candidate, VYD2311, also shows promise against these strains.
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Avacta Group partners with Tempus to enhance AI-driven oncology drug development
PharmaLogic opens new radiopharmaceutical facility in Salt Lake City
Astellas Pharma's VYLOY receives US FDA approval
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Elysium Health launches VISION for visual performance and eye health
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Innovent Biologic meets primary endpoint in picankibart phase 2 study